Literature DB >> 23818648

Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.

Benedetta Tomberli1, Franco Cecchi, Roberto Sciagrà, Valentina Berti, Francesca Lisi, Francesca Torricelli, Amelia Morrone, Gabriele Castelli, Magdi H Yacoub, Iacopo Olivotto.   

Abstract

AIMS: Male patients with Anderson-Fabry disease (AFD) often exhibit cardiac involvement, characterized by LV hypertrophy (LVH), associated with severe coronary microvascular dysfunction (CMD). Whether CMD is present in patients without LVH, particularly when female, remains unresolved. The aim of the study was to investigate the presence of CMD by positron emission tomography (PET) in AFD patients of both genders, with and without evidence of LVH. METHODS AND
RESULTS: We assessed myocardial blood flow following dipyridamole infusion (Dip-MBF) with 13N-labelled ammonia by PET in 30 AFD patients (age 51 ± 13 years; 18 females) and in 24 healthy controls. LVH was defined as echocardiographic maximal LV wall thickness ≥13 mm. LVH was present in 67% of patients (n = 20; 10 males and 10 females). Dip-MBF was reduced in all patients compared with controls (1.8 ± 0.5 and 3.2 ± 0.5 mL/min/g, respectively, P < 0.001). For both genders, flow impairment was most severe in patients with LVH (1.4 ± 0.5 mL/min/g in males and 1.9 ± 0.5 mL/min/g in females), but was also evident in those without LVH (1.8 ± 0.3 mL/min/g in males and 2.1 ± 0.4 mL/min/g in females; overall P = 0.064 vs. patients with LVH). Analysis of variance (ANOVA) for the 17 LV segments showed marked regional heterogeneity of MBF in AFD (F = 4.46, P < 0.01), with prevalent hypoperfusion of the apical region. Conversely, controls showed homogeneous LV perfusion (F = 1.25, P = 0.23).
CONCLUSIONS: Coronary microvascular function is markedly impaired in AFD patients irrespective of LVH and gender. CMD may represent the only sign of cardiac involvement in AFD patients, with potentially important implications for clinical management.

Entities:  

Keywords:  Coronary microvascular dysfunction; Early phenotype; Fabry disease; PET

Mesh:

Year:  2013        PMID: 23818648     DOI: 10.1093/eurjhf/hft104

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  16 in total

Review 1.  Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).

Authors:  Roberto Sciagrà; Alessandro Passeri; Jan Bucerius; Hein J Verberne; Riemer H J A Slart; Oliver Lindner; Alessia Gimelli; Fabien Hyafil; Denis Agostini; Christopher Übleis; Marcus Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-05       Impact factor: 9.236

Review 2.  Microvascular dysfunction in infiltrative cardiomyopathies.

Authors:  Ornella Rimoldi; Francesco Maranta
Journal:  J Nucl Cardiol       Date:  2017-07-11       Impact factor: 5.952

3.  Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis.

Authors:  Sharmila Dorbala; Divya Vangala; John Bruyere; Christina Quarta; Jenna Kruger; Robert Padera; Courtney Foster; Michael Hanley; Marcelo F Di Carli; Rodney Falk
Journal:  JACC Heart Fail       Date:  2014-07-09       Impact factor: 12.035

Review 4.  Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

Authors:  Aleš Linhart; Tomáš Paleček
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 5.  Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies.

Authors:  Paco E Bravo; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

Review 6.  Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review.

Authors:  Marco Giuseppe Del Buono; Rocco A Montone; Massimiliano Camilli; Salvatore Carbone; Jagat Narula; Carl J Lavie; Giampaolo Niccoli; Filippo Crea
Journal:  J Am Coll Cardiol       Date:  2021-09-28       Impact factor: 24.094

7.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

8.  Quantitative Myocardial Perfusion in Fabry Disease.

Authors:  Kristopher D Knott; Joao B Augusto; Sabrina Nordin; Rebecca Kozor; Claudia Camaioni; Hui Xue; Rebecca K Hughes; Charlotte Manisty; Louise A E Brown; Peter Kellman; Uma Ramaswami; Derralyn Hughes; Sven Plein; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2019-07-04       Impact factor: 7.792

Review 9.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 10.  Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

Authors:  Roberta Esposito; Ciro Santoro; Giulia Elena Mandoli; Vittoria Cuomo; Regina Sorrentino; Lucia La Mura; Maria Concetta Pastore; Francesco Bandera; Flavio D'Ascenzi; Alessandro Malagoli; Giovanni Benfari; Antonello D'Andrea; Matteo Cameli
Journal:  J Clin Med       Date:  2021-05-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.